MediciNova, Inc.
MNOV
MediciNova, Inc., a biopharmaceutical company, focuses on developing novel and small molecule therapeutics for the treatment of serious diseases with unmet medical needs in the United States. The company is developing MN-166 (ibudilast), an oral anti-inflammatory and neuroprotective agent for treating neurological disorders, such as primary and secondary progressive multiple sclerosis, amyotrophicā¦ read more
Healthcare
Biotechnology
18 years
USD
Exclusive to Premium users
Price
per share adjusted in USD$1.55
Price+0.65%
$0.01
1Y
Price
Market Cap
$76.022m
Small
Price/Earnings 3y Avg5y Avg
-
Premium
Premium
Financials Overview
Key metrics over the past few years-2676.1%
EBITDA Margin-2437.7%
Net Profit Margin-4521755.8%
Free Cash Flow MarginRevenue
$134.600k
-
1y CAGR-33.3%
3y CAGR-50.0%
5y CAGREarnings
-$11.812m
-6.9%
1y CAGR+1.1%
3y CAGR-8.9%
5y CAGREPS
-$0.24
-4.3%
1y CAGR+0.6%
3y CAGR-9.1%
5y CAGRBook Value
$46.857m
$49.824m
Assets$2.967m
Liabilities$301.880k
DebtDebt to Assets
0.6%
-
Debt to EBITDAFree Cash Flow
-$6.094b
-57153.9%
1y CAGR-19051.5%
3y CAGR-14297.9%
5y CAGRFinancial Reports
Earnings and other important metrics. Amounts in USD.No items found.
Press Releases
Statements and updates from the company